Market Overview

Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market

Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market
44 Biggest Movers From Yesterday
44 Biggest Movers From Friday
Rounds Report: Gemphire Enjoyed A Robust Appreciation Backed By Strong Fundamentals (Seeking Alpha)

Canaccord Genuity said Gemphire Therapeutics Inc (NASDAQ: GEMP)'s oral cholesterol drug Gemcabene has a peak U.S. market potential of $2.8 billion. The firm initiated coverage of the stock with a Buy rating.

The brokerage also set a price target of $17, implying a potential upside of 67 percent over Monday's close. On Tuesday, shares gaped open higher at $10.49 and have touched a new 52-week high of $11.33.

"Importantly, we feel gemcabene's oral formulation should enable pricing far below highly efficacious but expensive PCSK9 drugs, enabling meaningful uptake. Assuming positive data, we believe the drug could reach the US market in the broader cholesterol populations by 2020," analyst John Newman wrote in a note.

Related Link: Argus Upgrades AstraZeneca To Buy, Says Discount Is Too Steep Against Pipeline Potential

Gemcabene, which was licensed from Pfizer Inc. (NYSE: PFE), has shown no evidence of drug-drug interactions with statins at any statin dose level, which bodes well for the safety profile of the drug.

"Combination therapy with statins is critical since statins are the preferred therapy for high cholesterol and are generic. We believe that the ability to safely combine gemcabene with statins is also very important to FDA from a safety perspective, which we view as an advantage for the company," Newman added.

At time of writing, shares of Gemphire had climbed 11.45 percent on the day to $11.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for GEMP

May 2018Raymond JamesInitiates Coverage OnOutperform
Jan 2018H.C. WainwrightMaintainsBuyBuy
Nov 2017H.C. WainwrightMaintainsBuy

View More Analyst Ratings for GEMP
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (PFE + GEMP)

View Comments and Join the Discussion!